Abstract
Human UDP-glucuronosyltransferase (UGT) 2B7 is the major isoform catalyzing the glucuronidation of a variety of endogenous compounds including bile acids. To determine the role of bile acids in the regulation of UGT2B7 expression, Caco-2 cells were incubated with the natural human farnesoid X receptor (hFXR) ligand, chenodeoxycholic acid, as well as the secondary bile acid, lithocholic acid, derived from chenodeoxycholic acid. Incubation of Caco-2 cells with lithocholic acid in the absence of exogenous hFXR resulted in a dose-dependent down-regulation of UGT2B7 mRNA levels, with an IC50 of 13 μM. Similar down-regulation was also observed with chenodeoxycholic acid; however, much higher concentrations were required. Transient transfection of Caco-2 cells with hFXR suppressed UGT2B7 mRNA expression both in the absence and presence of ligand. UGT2B7 promoter transfection experiments and deletion/mutation analysis showed that lithocholic acid-activated hFXR decreased UGT2B7 promoter activity via a negative hFXR response element (NFRE) located between nucleotides –148 and –134. Cotransfection with hFXR and/or human retinoid X receptor further enhanced the repression. Electrophoretic mobility shift assays additionally confirmed the role of NFRE in UGT2B7 down-regulation by lithocholic acid. These findings suggest that lithocholic acid, an activator of nuclear hFXR, acts as a negative regulator of UGT2B7 expression, indicating that hFXR may play an essential role in lithocholic acid homeostasis through negative regulation of this UGT that is involved in lithocholic acid biotransformation. Therefore, it is postulated that lithocholic acid toxicity may be due to down-regulation of genes involved in its detoxification, including UGT2B7, leading to limited excretion of lithocholic acid from the body.
Footnotes
-
This work was supported in part by National Institutes of Health Grants DK56226 and DK60109 (A.R.-P.) and 20 RR016460 (T.L.). A.R-P. is also supported by tobacco settlement funds from University of Arkansas for Medical Sciences.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.104.003061.
-
ABBREVIATIONS: hFXR, human farnesoid X receptor; UGT, UDP-glucuronosyltransferase; I-BABP, ileal-bile acid-binding protein; PPAR, peroxisome proliferator-activated receptor; HepG2, human hepatocellular carcinoma cell line; Caco-2, human colorectal adenocarcinoma cell line; CREB, cyclic AMP response element-binding protein; hRXR, human retinoid X receptor; EMSA, electrophoretic mobility shift assay; PXR, pregnane X receptor; hPXR, human PXR; NFRE, negative farnesoid X receptor response element; hVDR, human vitamin D receptor; DMEM, Dulbecco's modified Eagle's medium; dNTP, deoxynucleoside-5′-triphosphate; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SSC, standard saline citrate; kb, kilobase(s); bp, base pair(s); IR-1, inverted repeat-1; Rif, rifampicin; SHP, small heterodimer partner; ANOVA, analysis of variance.
-
↵1 Current address: Unite de Biochimie-Pharmacologie-Toxicologie, Université de Bourgogne, Dijon, France.
- Received November 16, 2004.
- Accepted March 31, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|